Generex Begins Testing New Vaccine for Breast Cancer Patients

Generex Biotechnology has announced that the first patients had received a novel therapeutic vaccine developed by its wholly owned subsidiary, Antigen Express as part of the company's Phase I Trial.

The trial will include between 16 and 24 patients. The compound, AE37, is designed to stimulate an immune response against the tumor-causing gene HER-2/neu, which occurs in a significant percentage of patients with breast cancer as well as other cancers. A robust immune response against HER-2/neu has the potential to destroy tumor cells even at sites in the body distant from the primary tumor.